Dabigatran and mechanical heart valves - Not as easy as we hoped

New England Journal of Medicine

Volumn 369, Issue 13, 2013, Pages 1264-1266

  Hylek, Elaine M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; OPIATE; WARFARIN;

ANTICOAGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; EDITORIAL; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MECHANICAL HEART VALVE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOGENICITY;

EID: 84884521834     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1310399     Document Type: Editorial

References (8)

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:Suppl:e44S-e88S.
2. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002;123:715-23. (Pubitemid 34535082)
3. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.
4. Zwicker JI, Trenor CC III, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011;31:728-33.
5. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997;96:3534-41. (Pubitemid 27513430)
6. Biró E, Sturk-Maquelin KN, Vogel GM, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003;1:2561-8.
7. Drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. Silver Spring, MD: Food and Drug Administration, December 19, 2012 (http://www.fda.gov/Drugs/ DrugSafety/ucm332912.htm).
8. Summary of opinion (post authorisation): Pradaxa (dabigatran etexilate). London: European Medicines Agency, December 12, 2012 (http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion/human/000829/WC500136258.pdf).